

CITATION REPORT

List of articles citing

Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil

DOI: 10.1111/j.1743-6109.2009.01301.x

Journal of Sexual Medicine, 2009, 6, 2039-48.

Source: <https://exaly.com/paper-pdf/45991464/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
53	Sexual dysfunction in the older man. <i>Reviews in Clinical Gerontology</i> , 2009 , 19, 237-248		10
52	A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. <i>BJU International</i> , 2010 , 105, 1634-9	5.6	26
51	Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. <i>Journal of Sexual Medicine</i> , 2010 , 7, 2192-2200	1.1	28
50	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, i-xii	2.6	
49	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 159-71	4.4	23
48	Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil. <i>Yearbook of Urology</i> , 2010 , 2010, 163-164		
47	Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. <i>Journal of the American Academy of Nurse Practitioners</i> , 2011 , 23, 320-30		6
46	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	4	15
45	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. <i>Drugs and Aging</i> , 2012 , 29, 771-81	4.7	8
44	Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. <i>Korean Journal of Urology</i> , 2012 , 53, 377-85		8
43	Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2012 , 66, 813-820	2.9	7
42	How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2012 , 9, 26-33	1.1	24
41	Phosphodiesterase inhibitors in clinical urology. <i>Expert Review of Clinical Pharmacology</i> , 2013 , 6, 323-32	3.8	20
40	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , 2013 , 67, 768-80	2.9	73
39	Daily dosing of PDE5 inhibitors: where does it fit in?. <i>Current Urology Reports</i> , 2013 , 14, 269-78	2.9	5
38	Erectile dysfunction. <i>Lancet, The</i> , 2013 , 381, 153-65	4.0	545
37	Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1592-602	1.1	26

36	Retrospective analysis of the efficacy and safety of once-daily tadalafil in patient subgroups: men with mild vs moderate ED and aged . <i>International Journal of Impotence Research</i> , 2013 , 25, 91-8	2.3	2
35	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. <i>International Journal of Impotence Research</i> , 2014 , 26, 223-9	2.3	12
34	Erectile Dysfunction in Inflammaging. 2014 , 287-295		1
33	Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. <i>European Journal of Pharmacology</i> , 2014 , 744, 42-51	5.3	12
32	Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. <i>Drugs and Aging</i> , 2014 , 31, 425-39	4.7	10
31	Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. <i>International Journal of Clinical Practice</i> , 2014 , 68, 1087-99	2.9	15
30	Erectile dysfunction and cardiovascular disease. <i>Postgraduate Medicine</i> , 2015 , 127, 166-72	3.7	9
29	Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial. <i>Journal of Sexual Medicine</i> , 2015 , 12, 1194-201 ^{1.1}		7
28	Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. <i>Andrologia</i> , 2015 , 47, 20-4	2.4	19
27	Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. <i>International Journal of Impotence Research</i> , 2015 , 27, 33-7	2.3	9
26	Recruiting endogenous stem cells: a novel therapeutic approach for erectile dysfunction. <i>Asian Journal of Andrology</i> , 2016 , 18, 10-5	2.8	16
25	Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine. <i>Journal of the American Heart Association</i> , 2016 , 5, e003277	6	20
24	The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 141-52	4.1	35
23	Drugs for Treatment of Erectile Dysfunction. 2016 , 783-800		
22	Recent advances in the treatment of erectile dysfunction. <i>Postgraduate Medical Journal</i> , 2017 , 93, 679-685		50
21	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 183-192	5.5	19
20	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , 2018 , 35, 175-187	4.7	12
19	Selective and rapid determination of tadalafil and finasteride using solid phase extraction by high performance liquid chromatography and tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 152, 215-223	3.5	9

18	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2018 , 11, CD010060	5.2	8
17	Daily Oral L-Arginine Plus Tadalafil in Diabetic Patients with Erectile Dysfunction: A Double-Blinded, Randomized, Controlled Clinical Trial. <i>Journal of Sexual Medicine</i> , 2019 , 16, 1390-1397	1.1	9
16	Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction. <i>Sexual Medicine</i> , 2019 , 7, 282-291	2.7	9
15	Recent advances in the understanding and management of erectile dysfunction. <i>F1000Research</i> , 2019 , 8,	3.6	17
14	Chinese herbal medicine combined with tadalafil for erectile dysfunction: a systematic review and meta-analysis. <i>Andrology</i> , 2020 , 8, 268-276	4.2	5
13	Role of application of tadalafil 5 mg once-daily (8 months) in men with erectile dysfunction from six randomized controlled trials. <i>Translational Andrology and Urology</i> , 2020 , 9, 1405-1414	2.3	1
12	Novel Emerging Therapies for Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2021 , 39, 48-64	6.8	6
11	Sexual problems in diabetes. 2021 , 196-203		
10	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , e3494	7.5	6
9	Medical Treatment of LUTS/BPH. 2014 , 67-87		3
8	Diabetes Mellitus and Erectile Dysfunction. 2015 , 119-128		2
7	Management of Erectile Dysfunction After Radical Prostatectomy. 2015 , 217-224		
6	Erectile Dysfunctions. 2020 , 75-88		
5	A Prospective Randomized Comparative Study to Evaluate the Effect of Once Daily Dose of Tadalafil (5 mg) vs. On-Demand Tadalafil (10 mg) on International Index for Erectile Function (IIEF) Score. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2020 , 7, 2694-2699	0	
4	Effects of systemic tadalafil on skin flap survival in rats. <i>Eplasty</i> , 2012 , 12, e45	0.3	7
3	Tadalafil for Endometrial Growth in Clomiphene Citrate stimulated cycles in an IUI programma: A pilot study. <i>Facts, Views & Vision in ObGyn</i> , 2015 , 7, 231-237	1.4	1
2	Effects of phosphodiesterase 5 inhibition on cardiovascular function in resistant hypertension: A systematic review.. <i>Life Sciences</i> , 2022 , 291, 120270	6.8	
1	Comparison of three different tadalafil regimens for erectile dysfunction treatment in patients with diabetes mellitus microvascular complications.		

